title: Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding.
abstract: Emerging evidence indicates the potential involvement of ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, in low-grade inflammatory diseases such as obesity and atherosclerosis. The goal of the present study was to use cell culture models to investigate the influences of ghrelin and obestatin in processes participating in atherogenesis. We studied monocyte adhesion, monocyte chemoattractant protein-1, and adhesion molecule expression on endothelial cells as well as binding of oxidized low-density lipoprotein (LDL) and acetylated LDL to macrophages. Ghrelin treatment increased adhesion of calcein-labeled THP-1 monocytes to EA.hy 926 endothelial cells. Simultaneously, ghrelin increased the expression of intercellular adhesion molecule-1 measured by quantitative reverse transcriptase polymerase chain reaction. Tumor necrosis factor-alpha stimulation together with ghrelin treatment decreased both monocyte adhesion and vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression and, together with obestatin treatment, decreased vascular cell adhesion molecule-1 expression. Finally, ghrelin and obestatin increased binding of oxidized LDL to thioglycollate-elicited mouse peritoneal macrophages. No changes were observed in the uptake of acetylated LDL by mouse J774.A1 macrophages after exposure to ghrelin or obestatin. In conclusion, we found 3 lines of in vitro evidence supporting proatherogenic properties of ghrelin in the early stages of the disease. However, in the presence of tumor necrosis factor-alpha stimulation, opposite effects of ghrelin were observed, suggesting that ghrelin may also have an anti-inflammatory role in the presence of increased inflammation, for example, during the more progressed phases of atherogenesis.
authors.affiliation: Department of Internal Medicine and Biocenter Oulu, Institute of Clinical Medicine, University of Oulu and Clinical Research Center, Oulu University Hospital, Oulu, Finland. eija.kellokoski@oulu.fi
authors.forename: Eija
authors.initials: E
authors.lastname: Kellokoski
authors.forename: Anne
authors.initials: A
authors.lastname: Kunnari
authors.forename: Maarit
authors.initials: M
authors.lastname: Jokela
authors.forename: Sanna
authors.initials: S
authors.lastname: Mäkelä
authors.forename: Y Antero
authors.initials: YA
authors.lastname: Kesäniemi
authors.forename: Sohvi
authors.initials: S
authors.lastname: Hörkkö
mesh_terms: D000215:Acylation; D000818:Animals; D050197:Atherosclerosis / Q000473:pathology* / Q000517:prevention & control*; D002448:Cell Adhesion / Q000187:drug effects*; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000378:metabolism; D042783:Endothelial Cells / Q000187:drug effects; D054439:Ghrelin / Q000494:pharmacology*; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000187:drug effects*; D010084:Oxidation-Reduction; D011485:Protein Binding; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D015815:Cell Adhesion Molecules; D018932:Chemokine CCL2; D054439:Ghrelin; D008077:Lipoproteins, LDL; D014409:Tumor Necrosis Factor-alpha; C032629:acetyl-LDL; C099252:oxidized low density lipoprotein